1478 Dipeptidyl peptidase 4 (DPP4) inhibition is not solely responsible for the anti-tumor effects of BXCL701, an inhibitor of multiple DPPs, in a murine model of pancreatic ductal adenocarcinoma

• Vincent O’Neill,
• Veena Agarwal,
• Annie Zuo,
• Sandra A Jablonski,
• Louis M Weiner,
• Alexander Lekan,
• Rachael Maynard,
• Zoe X Malchiodi,
• Moses Donkor

Affiliations

Vincent O’Neill

Bioxcel Therapeutics, New Haven, CT, USA

Veena Agarwal

Immune-oncology, BioXcel Therapeutics Inc, New Haven, Connecticut, USA

Annie Zuo

Department of Oncology, Georgetown University Medical Center, Washington, DC, USA

Sandra A Jablonski

1Georgetown University/Lombardi Comprehensive Cancer Center, Washington, DC, USA

Louis M Weiner

Department of Oncology, Georgetown University Medical Center, Washington, DC, USA

Alexander Lekan

1Georgetown University/Lombardi Comprehensive Cancer Center, Washington, DC, USA

Rachael Maynard

1Georgetown University/Lombardi Comprehensive Cancer Center, Washington, DC, USA

Zoe X Malchiodi

1Georgetown University/Lombardi Comprehensive Cancer Center, Washington, DC, USA

Moses Donkor

3Onkosxcel Therapeutics, New Haven, CT, USA